NewLink Genetics Corp (NASDAQ:NLNK) saw strong trading volume on Monday . 441,000 shares were traded during trading, an increase of 96% from the previous session’s volume of 224,450 shares.The stock last traded at $9.91 and had previously closed at $10.31.

Several equities research analysts have recently commented on the company. Zacks Investment Research raised NewLink Genetics Corp from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a report on Tuesday, July 26th. Stifel Nicolaus reduced their target price on NewLink Genetics Corp from $63.00 to $23.00 and set a “buy” rating for the company in a report on Tuesday, May 10th. Robert W. Baird reaffirmed a “buy” rating on shares of NewLink Genetics Corp in a report on Monday, May 16th. Jefferies Group reaffirmed a “hold” rating and set a $10.00 target price on shares of NewLink Genetics Corp in a report on Wednesday, May 11th. Finally, SunTrust Banks Inc. downgraded NewLink Genetics Corp from a “buy” rating to a “neutral” rating and reduced their target price for the company from $59.00 to $12.00 in a report on Tuesday, May 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $23.29.

The stock has a 50 day moving average of $10.56 and a 200 day moving average of $14.03. The firm’s market capitalization is $287.08 million.

NewLink Genetics Corp (NASDAQ:NLNK) last released its earnings results on Friday, July 29th. The company reported ($1.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.35. On average, analysts predict that NewLink Genetics Corp will post ($3.06) earnings per share for the current year.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.